News - Tra
2007-10-22 06:00:15
KENILWORTH, N.J., Oct. 22 /PRNewswire/ -- Schering-Plough Corporation today provided an update on the clinical development program for its novel oral thrombin receptor antagonist (TRA).
KENILWORTH, N.J., Oct. 22 /PRNewswire/ -- Schering-Plough Corporation today provided an update on the clinical development program for its novel oral thrombin receptor antagonist (TRA).